Influence of co-mediaction in response to Tnf-Inhibitors (infliximab, etanercept, adalimumab, golimumab and certolizumab) in patients with spondyloarthritis
Latest Information Update: 23 Jun 2021
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
- Indications Ankylosing spondylitis; Axial spondyloarthritis; Spondylarthritis
- Focus Therapeutic Use
Most Recent Events
- 05 Jun 2021 Results assessing whether Proton Pump Inhibitors impair response to Tnf-Inhibitors in spondyloarthritis patients, presented at the 22nd Annual Congress of the European League Against Rheumatism
- 27 Jun 2020 New trial record
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism